Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Collagen thread boosts lymphedema surgery? stanford trial begins

NCT ID NCT05825157

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a special collagen thread called BioBridge to standard lymph node transfer surgery can better reduce arm swelling in people with lymphedema. About 60 adults with stage I-II arm lymphedema will be followed for 12 months to measure changes in limb volume. The goal is to see if the scaffold helps new lymphatic connections form, improving the surgery's success rate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BioBridge scaffold (a thread-like collagen device) used alongside standard lymph node transfer surgery
What this could lead to
If it works, this could improve surgical outcomes for people with arm lymphedema, reducing swelling more effectively than surgery alone.
What could go wrong
This is a small, early-stage trial with only 60 people. The device is new, and it may not improve results or could cause complications like infection or scarring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 18 to 75 years (inclusive) * Life expectancy \> 2 years * Upper limb lymphedema * The participant must be eligible for surgical intervention * Swelling of 1 limb that is not completely reversed by elevation or compression * Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system * Participants with a history of cancer must have no evidence of disease (NED), have completed breast cancer therapy 3 years prior to enrollment; use of endocrine therapy is allowed. * Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen * Willingness to comply with recommended regimen of self care, with consistent use of compression garments from screening through the entire study duration (through the safety follow up visit), excluding the first 3 weeks postoperatively where patients are required to not wear compression. Self bandaging, use of nighttime compression garments, and intermittent pneumatic compression devices are allowed, but the procedures and regimens are expected to remain consistent from screening though the entire study duration. * Consistent use of an appropriately sized compression garment for daytime use. * Limb volume (LV) in the affected limb and unaffected limb must be at least 10% of each other. * Evidence of abnormal bioimpedance ratio, if feasible, based upon unilateral disease: L Dex \> 10 units. * Willingness and ability to comply with all study procedures, including measurement of limb volume, skin biopsy, and preoperative and postoperative imaging studies. * Willingness and ability to understand, and to sign a written informed consent form document Exclusion Criteria: * Edema arising from increased capillary filtration will be excluded (venous incompetence). * Inability to safely undergo general anesthesia and/or perioperative care related to vascularized lymph node transfer * Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half life, whichever is longer * Recent initiation (≤ 12 weeks) of CDPT for lymphedema * Other medical condition that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure * Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion) * History of clotting disorder (hypercoagulable state) * Chronic (persistent) infection in the affected limb * Infection of the lymphedema limb within 1 month prior to screening * Currently receiving chemotherapy or radiation therapy * Body Mass Index (BMI) \>35 * Known sensitivity to porcine products * Anaphylaxis to iodine * Pregnancy or nursing * Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening * Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphedema arm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stanford Hospital and Clinics

    RECRUITING

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.